UTHR : Summary for United Therapeutics Corporation - Yahoo Finance

U.S. Markets closed

United Therapeutics Corporation (UTHR)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
152.51+5.80 (+3.95%)
At close: 4:00PM EST
People also watch
ALXNBMRNVRTXMDCOMYGN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close146.71
Open146.77
Bid152.25 x 100
Ask0.00 x
Day's Range146.77 - 152.95
52 Week Range97.52 - 169.89
Volume562,270
Avg. Volume602,101
Market Cap6.86B
Beta1.35
PE Ratio (TTM)10.32
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journals4 days ago

    United Therapeutics feels squeeze from increased pulmonary hypertension competition

    United Therapeutics Corp. (UTHR) blames increasing competition in the pulmonary arterial hypertension space for its lower-than-expected revenue last year, CEO Martine Rothblatt told analysts Wednesday. During the Silver Spring-based company's fourth-quarter earnings call, Rothblatt said there has been weaker growth for some of its drugs — Orenitram, Tyvaso and Remodulin. Patients are sticking with alternative therapies, such as a combination of Adcirca with Letairis, longer than expected before switching to its products, she said.

  • United Therapeutics Corp. :UTHR-US: Earnings Analysis: 2016 By the Numbers : February 23, 2017
    Capital Cube4 days ago

    United Therapeutics Corp. :UTHR-US: Earnings Analysis: 2016 By the Numbers : February 23, 2017

    Categories: Yahoo Finance Get free summary analysis United Therapeutics Corp. reports financial results for the year ended December 31, 2016. We analyze the earnings along side the following peers of United Therapeutics Corp. – Eli Lilly and Company, Gilead Sciences, Inc., Teva Pharmaceutical Industries Limited Sponsored ADR, Pfizer Inc., Baxter International Inc., Cytokinetics, Incorporated, GlaxoSmithKline plc Sponsored ADR ... Read more (Read more...)

  • United Therapeutics (UTHR) Down on Q4 Earnings & Sales Miss
    Zacks4 days ago

    United Therapeutics (UTHR) Down on Q4 Earnings & Sales Miss

    United Therapeutics Corporation (UTHR) reported adjusted earnings of $2.64 per share for fourth-quarter 2016, which missed the Zacks Consensus Estimate of $3.62 by 27.1%.